BridgeBio Pharma Inventory 2018-2024 | BBIO

BridgeBio Pharma inventory from 2018 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
BridgeBio Pharma Annual Inventory
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
BridgeBio Pharma Quarterly Inventory
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.392B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00